Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis.

Pratyusha ChitturiShiwen XuBahja Ahmed AbdiJohn NguyenDavid E CarterSarthak SinhaRohit AroraJeff BiernaskieRichard J StrattonAndrew Leask

Published in: Annals of the rheumatic diseases (2023)

Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis.

Keyphrases

systemic sclerosis
interstitial lung disease
soft tissue
wound healing
liver fibrosis
rheumatoid arthritis
machine learning
human health
pulmonary fibrosis
climate change
water soluble
artificial intelligence